What Is Parkinson Disease?
Parkinson Disease (PD) is a chronic and progressive neurodegenerative condition that predominantly affects the motor system. It is the second most common neurodegenerative disease in the world, behind only Alzheimer disease.
The disease results from the progressive degeneration of dopaminergic neurons in the substantia nigra of the midbrain. Loss of these neurons reduces the availability of dopamine in the basal ganglia, brain circuits essential for fine control of voluntary movement.
Although classically described as a motor disorder, PD is now recognized as a multisystem disease. Non-motor symptoms — such as sleep disturbances, depression, constipation, and loss of smell — frequently precede the motor symptoms by years or even decades.
Dopaminergic Degeneration
Loss of dopamine-producing neurons in the substantia nigra is the disease's central mechanism.
Beyond Movement
Non-motor symptoms such as depression, constipation, and sleep disturbances are integral to the disease.
Gradual Progression
The disease progresses slowly over years. Motor symptoms appear once 60-80% of dopaminergic neurons have already been lost.
Epidemiology
Parkinson disease affects approximately 1-2% of the population over age 60, with incidence rising with age. It is slightly more prevalent in men than in women, at a ratio of about 1.5:1. The mean age of onset is between 55 and 65 years, although early-onset forms (before age 40) account for 5-10% of cases.
Established risk factors include advanced age, male sex, family history, and exposure to pesticides or herbicides. Curiously, caffeine and tobacco use are associated with lower risk — although tobacco use is not recommended given its other health risks.
Pathophysiology
The central mechanism of PD is the degeneration of dopaminergic neurons in the pars compacta of the substantia nigra. These neurons project to the striatum (caudate and putamen), forming the nigrostriatal pathway, essential for the modulation of voluntary movement.
The histopathologic hallmark of the disease is the Lewy bodies — cytoplasmic inclusions composed predominantly of aggregated alpha-synuclein. The Braak hypothesis proposes that alpha-synuclein pathology spreads in an ascending manner, beginning in the olfactory bulb and the enteric nervous system, progressing to the brainstem, and finally reaching the cerebral córtex.
Dopamine normally balances the activity of two pathways in the basal ganglia: the direct pathway (which facilitates movement) and the indirect pathway (which inhibits unnecessary movements). Dopaminergic depletion results in hypoactivity of the direct pathway and hyperactivity of the indirect pathway, producing bradykinesia and rigidity.
Cellular mechanisms driving neurodegeneration include mitochondrial dysfunction, oxidative stress, microglia-mediated neuroinflammation, ubiquitin-proteasome system dysfunction, and pathologic alpha-synuclein aggregation. Genetic factors (mutations in SNCA, LRRK2, Parkin, PINK1) and environmental factors interact to determine individual risk.
Symptoms
The classic motor symptoms of PD are often summarized by the acronym TRAP: resting Tremor, Rigidity, Akinesia/bradykinesia, and Postural instability. Onset is typically asymmetric, affecting one side of the body before the other.
Cardinal Motor Symptoms
- 01
Resting tremor
4-6 Hz rhythmic tremor, typically described as "pill-rolling" or "money-counting". It begins in one hand and is most evident at rest, decreasing with voluntary movement.
- 02
Bradykinesia
Progressive slowing of movement. Micrographia (progressively smaller handwriting), hypomimia (reduced facial expression), and reduced arm swing while walking.
- 03
Rigidity
"Cogwheel" type increase in muscle tone — interrupted resistance to passive movement. Present in limbs, trunk, and neck.
- 04
Postural instability
Loss of postural reflexes and a tendency to fall. Typically appears in more advanced stages of the disease.
- 05
Festinating gait
Short, shuffling steps with involuntary acceleration. Difficulty initiating gait ("freezing") and turning.
- 06
Hypophonia
Reduced vocal volume and monotone speech, hindering communication.
Non-Motor Symptoms
- 01
Hyposmia/anosmia
Partial or total loss of smell — may precede motor symptoms by years.
- 02
REM sleep behavior disorder
The patient "acts out" dreams during REM sleep, possibly kicking, punching, or shouting. Strong predictor of future PD.
- 03
Constipation
Reduced intestinal motility, often present years before motor diagnosis.
- 04
Depression and anxiety
Affect 40-50% of patients. Linked to both the disease's neurochemistry and its functional impact.
- 05
Cognitive dysfunction
Slowed processing and executive difficulty. Dementia may occur in advanced stages.
- 06
Orthostatic hypotension
Drop in blood pressure on standing, causing dizziness or fainting. Reflects autonomic dysfunction.
Diagnosis
The diagnosis of Parkinson disease is essentially clinical, based on history and neurologic examination. There is no laboratory or imaging test that definitively confirms the disease in life. The central diagnostic criterion is the presence of bradykinesia associated with resting tremor and/or rigidity.
Imaging studies such as brain MRI are normal in PD but are useful to rule out other causes. DaTscan (dopamine transporter scintigraphy) can demonstrate reduced dopaminergic uptake in the striatum, helping in the differential diagnosis with essential tremor.
🏥MDS (Movement Disorder Society) Diagnostic Criteria
Fonte: Postuma et al., 2015 — MDS Clinical Diagnostic Criteria
Essential Criterion
Mandatory for diagnosis- 1.Parkinsonism: bradykinesia + resting tremor AND/OR rigidity
Supporting Criteria
- 1.Clear and dramatic response to dopaminergic therapy
- 2.Presence of levodopa-induced dyskinesias
- 3.Documented resting tremor in a limb
- 4.Olfactory loss or cardiac denervation on MIBG scintigraphy
Absolute Exclusion Criteria
- 1.Unequivocal cerebellar signs
- 2.Supranuclear vertical gaze palsy
- 3.Diagnosis of frontotemporal dementia or primary progressive aphasia
- 4.Parkinsonism restricted to the lower limbs for more than 3 years
- 5.Use of dopaminergic blockers (drug-induced parkinsonism)
DIFFERENTIAL DIAGNOSIS OF PARKINSONISM
| CONDITION | DISTINGUISHING FEATURES | LEVODOPA RESPONSE |
|---|---|---|
| Parkinson Disease | Asymmetric, resting tremor, slow progression | Excellent |
| Essential Tremor | Action/postural tremor, bilateral, family history | None |
| Progressive Supranuclear Palsy | Vertical gaze palsy, early falls, axial rigidity | Poor |
| Multiple System Atrophy | Severe dysautonomia, cerebellar signs | Poor to moderate |
| Vascular Parkinsonism | Predominant gait, no tremor, vascular risk factors | Poor |
| Drug-Induced Parkinsonism | Symmetric, use of antipsychotics/metoclopramide | Variable (resolves on discontinuation) |
Differential Diagnosis
Parkinsonism — the syndrome of bradykinesia, rigidity, and tremor — can have several causes besides idiopathic Parkinson disease. Correct diagnosis is essential because treatment and prognosis differ significantly.
DIFFERENTIAL DIAGNOSIS
Differential Diagnosis
Essential Tremor
Read more →- Action tremor (not resting)
- Bilateral, symmetric
- No rigidity or bradykinesia
- Family history
Diagnostic Tests
- Neurologic examination
- DaTscan if needed
Drug-Induced Parkinsonism
- Use of dopaminergic blockers
- Metoclopramide, haloperidol
- Bilateral and symmetric
Diagnostic Tests
- Medication history
- Improvement after discontinuation
Multiple System Atrophy
- Early autonomic dysfunction
- Frequent falls
- Poor levodopa response
Diagnostic Tests
- MRI (putaminal atrophy)
- Autonomic tests
Progressive Supranuclear Palsy
- Early backward falls
- Impaired vertical gaze
- Erect (not stooped) posture
Diagnostic Tests
- MRI (penguin sign)
- Vertical gaze examination
Vascular Parkinsonism
- Festinating gait more than tremor
- Ischemic white matter lesions
- Poor levodopa response
Diagnostic Tests
- MRI with lacunar lesions
Parkinson Disease vs. Essential Tremor
Essential tremor is the most common differential diagnosis in clinical practice. Distinguishing the two is essential because treatment is completely different. The main differences: PD tremor occurs at rest (appears when the limb is at rest and decreases with voluntary movement), whereas essential tremor is an action/postural tremor (appears when sustaining a position or during movement). PD is unilateral or asymmetric at onset; essential tremor is bilateral and symmetric. PD requires bradykinesia and rigidity; essential tremor does not. Family history is more common in essential tremor. DaTscan shows reduced dopaminergic uptake in PD and is normal in essential tremor, potentially resolving ambiguous cases.
Drug-induced parkinsonism is often underdiagnosed. Metoclopramide (used for nausea and gastroparesis), haloperidol, risperidone, quetiapine, and other antipsychotics block dopaminergic receptors and can cause parkinsonism clinically identical to idiopathic PD. The distinguishing feature is that drug-induced parkinsonism is typically bilateral and symmetric (unlike PD, which is asymmetric). Careful review of current medications and improvement after discontinuation confirm the diagnosis. DaTscan is normal in drug-induced parkinsonism.
Multiple System Atrophy and PSP: Atypical Parkinsonisms
Multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are called "atypical parkinsonisms" or "Parkinson-plus syndromes". They have a worse prognosis than PD and respond poorly to levodopa — an important clinical clue. MSA is characterized by early, prominent autonomic dysfunction (severe orthostatic hypotension, sexual dysfunction, urinary incontinence) and often cerebellar signs. PSP has these distinguishing features: early backward falls (within the first year), vertical gaze palsy (inability to move the eyes up and down), erect axial posture (PD patients tend to stoop, PSP patients remain erect), and absence of tremor.
Vascular parkinsonism prominently affects gait (broad-based gait, short steps, "magnetic gait") with less resting tremor than idiopathic PD. It occurs in patients with multiple vascular risk factors and extensive white-matter ischemic lesions on MRI. Levodopa response is poor. Recognizing these atypical parkinsonisms is important for accurate prognostic counseling for patient and family.
Levodopa Response as a Diagnostic Tool
A clear, sustained response to levodopa (at least 30% improvement in motor symptoms) is a supporting diagnostic criterion for idiopathic PD in the MDS criteria. In practice, a therapeutic levodopa trial at adequate dose (titrated to tolerance, typically up to 600-1000 mg/day over 3-4 weeks, under neurologist supervision — higher initial doses may cause orthostatic hypotension, nausea, and confusion in elderly patients) can help distinguish idiopathic PD from atypical parkinsonisms. A dramatic, sustained response favors PD; a poor or absent response should raise suspicion of MSA, PSP, or vascular parkinsonism.
In ambiguous cases, especially when distinguishing PD from essential tremor, DaTscan (dopamine transporter scintigraphy) shows reduced striatal uptake in PD and is normal in essential tremor and drug-induced parkinsonism. It is a high-cost test but can be decisive in clinically ambiguous cases.
Treatment
There is no curative treatment for Parkinson disease. The therapeutic objective is to control symptoms and maintain quality of life for as long as possible. Treatment is individualized, considering age, predominant symptoms, functional impact, and comorbidities.
Initial Phase
First 1-5 yearsMild symptoms. Treatment can start with MÃO-B inhibitors (rasagiline, selegiline) or dopamine agonists in young patients. Levodopa is preferred in older patients or those with greater functional impairment.
Honeymoon Phase
3-7 years of treatmentGood medication response with stable symptom control. Levodopa produces sustained response throughout the day.
Phase of Motor Complications
After 5-10 yearsMotor fluctuations (wearing-off, on-off) and levodopa-induced dyskinesias emerge, requiring frequent adjustments and combination therapies.
Advanced Phase
VariableRefractory symptoms, dysphagia, dementia, and falls. Consider advanced therapies: deep brain stimulation (DBS) or continuous levodopa/apomorphine infusion.
MAIN MEDICATIONS FOR PARKINSON DISEASE
| CLASS | EXAMPLES | MECHANISM | MAIN INDICATION |
|---|---|---|---|
| Levodopa/Carbidopa | Prolopa, Sinemet | Dopamine precursor + peripheral decarboxylase inhibitor | Most effective treatment; gold standard |
| Dopamine agonists | Pramipexole, rotigotine | Directly stimulate dopamine receptors | Initial monotherapy in young patients; adjuvant |
| MÃO-B inhibitors | Rasagiline, selegiline | Inhibit dopamine degradation | Initial phase; adjuvant for fluctuations |
| COMT inhibitors | Entacapone, opicapone | Prolong levodopa action | Motor fluctuations (wearing-off) |
| Anticholinergics | Biperiden, trihexyphenidyl | Reduce relative cholinergic activity | Predominant tremor in young patients |
| Amantadine | Amantadine | NMDA antagonist + increased dopamine | Levodopa-induced dyskinesias |
Acupuncture as Treatment
Acupuncture is used as a complementary therapy in Parkinson disease, not as a substitute for conventional pharmacologic treatment. Preclinical and clinical studies suggest potential benefits for specific symptoms, although the evidence is still considered moderate by the scientific community.
Hypothesized mechanisms, derived predominantly from preclinical models, include potential modulation of dopamine release in the striatum, possible reduction of neuroinflammation, influence on neurotrophic factors (GDNF, BDNF), and modulation of the hypothalamic-pituitary-adrenal axis. Studies in animal models of Parkinson suggest that electroacupuncture may attenuate the loss of dopaminergic neurons in the substantia nigra — findings that still require validation in humans before clinical extrapolation.
In clinical practice, acupuncture can help manage symptoms such as musculoskeletal pain, constipation, insomnia, anxiety, and fatigue — non-motor symptoms that significantly affect quality of life and are not always well controlled by medication.
Prognosis
Parkinson disease is progressive, but the rate of progression varies considerably among patients. With adequate treatment, many patients maintain good function for 10-20 years or more. Life expectancy is slightly reduced compared with the general population but has improved significantly with current therapies.
Factors associated with a better prognosis include tremor-predominant onset, young age at diagnosis, and good levodopa response. Factors associated with a worse prognosis include early postural instability, cognitive dysfunction, hallucinations, and advanced age at diagnosis.
Myths and Facts
Myth vs. Fact
Parkinson is just tremor.
Tremor is the most visible symptom, but PD includes bradykinesia, rigidity, balance problems, and a wide range of non-motor symptoms such as depression, constipation, and sleep disturbances.
Myth vs. Fact
Levodopa should be delayed as much as possible to 'save' its effect.
Current evidence does not support this practice. Delaying levodopa does not prolong its long-term effect and can needlessly worsen the patient's quality of life. Motor complications depend more on disease progression than on how long the medication has been used.
Myth vs. Fact
Parkinson disease only affects older adults.
Although more common after age 60, 5-10% of cases begin before age 40 (early-onset Parkinson). Juvenile cases, though rare, can occur before age 20.
Myth vs. Fact
Nothing can be done to slow progression.
Regular physical exercise is the non-pharmacologic intervention with the most consistent evidence of a potential neuroprotective effect in PD; this is an observational association from cohort studies, not definitive proof of disease modification. Aerobic exercise and activities such as tai chi show benefits in motor function and may influence disease progression.
When to Seek Help
Early diagnosis of Parkinson disease allows timely treatment and better long-term planning. See a neurologist if you have any of the following signs:
Evaluation by a neurologist specialized in movement disorders is ideal to ensure accurate diagnosis and an individualized treatment plan. Multidisciplinary follow-up — including physical therapy, speech-language pathology, occupational therapy, and psychological support — is essential to optimize quality of life throughout the course of the disease.
Frequently Asked Questions
Frequently Asked Questions
There is no curative treatment for Parkinson disease yet. Current treatments — mainly levodopa — control symptoms and significantly improve quality of life but do not halt neurodegeneration. However, research into anti-alpha-synuclein immunotherapies, gene therapy, and stem cells offers promising prospects for the future. Physical exercise is the only intervention with evidence of a potential neuroprotective effect in humans.
Current evidence does not support delaying levodopa to "save" its effect — this practice does not prolong the therapeutic window and unnecessarily impairs quality of life. The indication for levodopa is based on the functional impact of symptoms: when bradykinesia, rigidity, or tremor begin to interfere with work, daily activities, or quality of life, it is time to start. In younger patients (under age 60), one can start with dopamine agonists or MÃO-B inhibitors to delay the long-term motor complications of levodopa.
Motor fluctuations are variations in medication efficacy throughout the day: "on" periods (good response) and "off" periods (return of symptoms). Wearing-off is the reduction of effect before the next dose. Dyskinesias are involuntary movements (writhing, swaying) that generally occur at the peak of levodopa effect. They appear after 5-10 years of levodopa treatment in many patients. Management strategies include: adjustment of levodopa dose and frequency, addition of COMT inhibitors, dopamine agonists, amantadine, and, in selected cases, deep brain stimulation.
No. Deep brain stimulation is indicated for patients with confirmed idiopathic PD, a prior good response to levodopa, disabling motor fluctuations or dyskinesias unresponsive to pharmacologic adjustment, no significant dementia, and good clinical condition for surgery. Poor levodopa response, dementia, and atypical parkinsonisms are relative contraindications. DBS does not cure the disease, but it can dramatically improve quality of life in selected patients.
Yes, it is one of the highest-evidence interventions in PD. Aerobic exercise, strength training, tai chi, Argentine tango, and dance show benefits for balance, gait, bradykinesia, fatigue, and quality of life. Studies in animal models and humans suggest neuroprotective effects via release of BDNF and other neurotrophic factors. The recommendation is at least 150 minutes of moderate aerobic exercise per week, plus additional balance and coordination training. Programs supervised by physical educators experienced in PD are ideal.
Acupuncture can be considered an adjunct among non-pharmacologic approaches for PD non-motor symptoms that often respond only partially to levodopa: musculoskeletal pain, constipation, insomnia, anxiety, and fatigue. Meta-analyses and systematic reviews (Lee 2008 Cochrane, later updates, and clinical trials from Chinese groups) suggest that acupuncture, as an adjunct to conventional treatment, may improve motor scores (UPDRS) in some patients. Methodologic quality is heterogeneous, and studies vary in protocol, sample size, and risk of bias — the effects do not include modifying the natural course of the disease. The medical acupuncturist can integrate acupuncture into an individualized treatment plan without replacing dopaminergic medication or altering neurodegenerative progression.
No — PD is now recognized as a multisystem disease. Non-motor symptoms are integral and often have the greatest impact on quality of life: depression and anxiety (40-50%), cognitive dysfunction (may progress to dementia in 30-40% of cases), sleep disturbances (insomnia, REM sleep behavior disorder), constipation (present in 80%), orthostatic hypotension, sexual dysfunction, pain, and fatigue. These non-motor symptoms often precede motor ones by years.
In most cases, no — at least not immediately. An early PD diagnosis generally allows patients to continue working for several years with adequate treatment. The decision depends on the type of work, the degree of motor impairment, and the response to medication. Activities requiring fine manual dexterity, balance in risky situations, or professional driving may be affected sooner. Occupational therapy support is essential for adaptations and maintaining productivity.
REM sleep behavior disorder (RBD) is a condition in which the patient "acts out" dreams during sleep — possibly kicking, punching, shouting, or falling out of bed. It is highly predictive of future neurodegeneration: approximately 75-90% of patients with idiopathic REM sleep behavior disorder convert to PD, multiple system atrophy, or dementia with Lewy bodies over 12-15 years in cohort studies (Postuma 2019). It is considered a marker of PD prodrome. Its recognition is important because it can identify PD years before motor symptoms, opening windows for early intervention.
Most PD cases (90-95%) are sporadic, with no clear family history. Identified genetic mutations (LRRK2, Parkin, PINK1, SNCA, GBA) explain only 10-15% of cases. The risk for first-degree relatives of patients with sporadic PD is 2-4 times that of the general population — a real increase, but still low in absolute terms. Mutations in the GBA gene (associated with Gaucher disease) are the most common genetic risk factor in PD and can be investigated in patients with a family history or early onset.
Related Reading
Deepen your knowledge with related articles